Last updated: 2026-09-10 07:24:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $3.51, with a market capitalization of $2.07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.58 to $55.90. This page covers its latest market performance, valuation, price trends and company information.
$2.07M | |
$3.50 | |
$252,520.00 | |
$2.58 | |
$3.54 | |
10.99K | |
2.12M | |
-- | |
$55.90 | |
$2.58 | |
-- | |
-- |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) last closed at $3.54 as of 2026-09-09 23:53:00, unchanged from the previous close of $3.54.
During the latest regular trading session, SHPH traded between $2.58 and $252,520.00, with a volume of 10.99K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Shuttle Pharmaceuticals Holdings, Inc. (SHPH) moved from $3.36 to $3.51, representing a gain of 4.46% ($0.15).
The stock traded between $3.36 and $4.10 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 39.25 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.8%
SHPH is currently trading at $3.51, placing it 1.8% of the way from its 52-week low of $2.58 to its 52-week high of $55.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Shuttle Pharmaceuticals Holdings, Inc. (SHPH) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.